Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the Acorai Heart Monitor, a handheld device designed to non-invasively measure pressures inside the heart in patients with heart failure. This observational study aims to assess the feasibility of using the Acorai device to predict survival, death, or major adverse cardiac events in patients who have been hospitalized with acute decompensated heart failure and are awaiting discharge home. The need for such a tool arises because current intracardiac pressure measurements require invasive right heart catheterization, which carries risks to patients. The Acorai Heart Monitor is an extended smartphone case equipped with various sensors that detect low-frequency sound and seismic signals related to intracardiac pressure. During the study, patients will have the device placed on their chest for five minutes while lying down, along with a small smart wristwatch to collect data. The study is single-arm, non-randomized, and non-significant risk, focusing on collecting non-invasive cardiac output measurements to evaluate the Acorai systems ability to predict outcomes. Participants will be patients recently hospitalized for decompensated heart failure who have received intravenous diuretic therapy and are medically fit for discharge. Researchers will monitor and assess intracardiac pressure data collected by the Acorai device and compare it with clinical outcomes over one year, including survival and hospital readmission. The primary outcome is the feasibility of predicting survival and hospitalization at one year. Secondary outcomes include predicting major adverse cardiac events and identifying which measurements best predict prognosis. The study is expected to last at least one year for each participant.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide compared to placebo in people with opioid use disorder OUD who are also receiving buprenorphine treatment, with or without naloxone. This Phase 2 study includes participants with mild to severe OUD and aims to assess abstinence from opioid use over a defined period. The study has two parts Part A involves a double-blind treatment phase followed by an open-label extension, while Part B includes only open-label treatment. Participants receive brenipatide or placebo by subcutaneous injection alongside buprenorphine administered under the tongue or in the cheek. Each participant enrolls in only one part, with treatment durations up to approximately 144 weeks in Part A and 116 weeks in Part B. Participants attend regular study visits for assessments, including urine drug screens and self-reports to measure opioid abstinence, adherence to buprenorphine, and changes in craving and quality of life. Other evaluations include monitoring for overdose events, healthcare utilization, body measurements, and blood pressure. Safety is tracked through laboratory tests and antibody monitoring, with the overall study lasting up to several years depending on enrollment timing.
Actively Recruiting
Researchers are studying an experimental drug called odronextamab combined with chemotherapy in patients with Diffuse Large B-cell Lymphoma DLBCL. This includes adults with untreated DLBCL as well as those whose disease has returned or not responded to treatment. The study aims to evaluate the safety, dosing, and effectiveness of odronextamab plus chemotherapy compared to the current standard treatment, rituximab combined with chemotherapy. The study is divided into Part 1A and 1B, which focus on determining safe doses and schedules of odronextamab combined with chemotherapy drugs including cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. Part 2 is a randomized comparison where participants receive either odronextamab plus chemotherapy or rituximab plus chemotherapy. Odronextamab and rituximab are given by intravenous infusion, with rituximab also possibly given subcutaneously. Participants will be monitored for side effects, disease progression, and quality of life over time. Assessments include measuring drug levels in the blood, immune response to the drug, and physical functioning questionnaires. The study will follow participants for up to five years to evaluate progression-free survival and other outcomes. Safety and adverse events will be tracked for up to two years.
Actively Recruiting
Researchers are evaluating two types of stereotactic body radiotherapy SBRT in men with high risk localized prostate cancer, where the cancer is confined to the prostate but may grow quickly or spread. The study aims to compare the safety and effectiveness of delivering radiotherapy to the prostate alone versus the prostate plus surrounding lymph nodes, with both treatments given in only 5 sessions. This phase III trial is designed to see if including lymph nodes reduces the chance of cancer returning and to review any side effects that occur. Participants will be randomly assigned to one of two groups. One group will receive SBRT targeting the prostate and seminal vesicles, delivering 36.25Gy in 5 fractions on alternate days with 40Gy to the prostate clinical target volume. The other group will get the same prostate treatment plus 25Gy in 5 fractions to the pelvic lymph nodes on alternate days. Treatments will be provided over approximately two weeks at experienced NHS radiotherapy centers that meet quality standards for these therapies. During the study, participants will be monitored for at least three and a half years to assess time to biochemical or clinical failure, which is the main outcome. Researchers will also track acute and late side effects, cancer relapse, survival rates, patient-reported outcomes, and adherence to treatment protocols for up to five years post-randomization. Regular imaging and assessments will be performed before treatment to confirm eligibility and exclude metastatic disease. Overall, participants can expect close monitoring and follow-up throughout and after their treatment period.
Actively Recruiting
Researchers are evaluating an experimental drug called odronextamab combined with lenalidomide for adults with relapsed or refractory Follicular Lymphoma FL or Marginal Zone Lymphoma MZL, which are subtypes of Non-Hodgkins Lymphoma NHL. This Phase 3 study includes two parts Part 1 to assess safety and dosing of the combination, and Part 2 to compare its effectiveness and safety against the current standard treatment of rituximab plus lenalidomide. The combination of odronextamab and lenalidomide is a first-in-human treatment being explored in this trial. In Part 1, participants receive odronextamab with lenalidomide to evaluate safety and determine dosing. In Part 2, participants are randomly assigned to receive either odronextamab plus lenalidomide or rituximab plus lenalidomide followed by lenalidomide alone, allowing comparison between the new combination and standard care. Both treatment combinations are administered according to the study protocol. Participants will be monitored for side effects, treatment tolerability, and disease progression through scheduled assessments including imaging scans and laboratory tests. Researchers will measure drug levels in the blood, immune responses against odronextamab, and quality of life impacts using questionnaires. Safety monitoring continues for up to two years, while efficacy outcomes such as progression-free survival and response duration are followed for up to five years, with ongoing evaluations throughout the study period.
Actively Recruiting
Researchers are studying severe diabetic macular oedema DMO, a condition where fluid builds up in the central part of the retina called the macula, leading to vision loss. The study compares two treatments for people with diabetes who have severe DMO, defined by a thickened macula of 400 microns or more. The goal is to find out if starting with anti-VEGF injections followed by subthreshold micropulse laser SML treatment when the macula thickness decreases below 400 microns is as effective and more cost-effective than continuing anti-VEGF injections alone. Participants are randomly assigned to one of two groups one receives anti-VEGF injections alone, which are given monthly at first and then every 1 to 3 months as needed the other group starts with anti-VEGF injections and switches to SML treatment every 2 to 3 months once the macula thickness is less than 400 microns. The anti-VEGF drugs used include ranibizumab, aflibercept, faricimab, and brolucizumab, and SML is a laser procedure that does not damage the macula. Treatment continues until the diabetic macular oedema clears. During the study, participants attend regular clinic visits for eye exams including optical coherence tomography OCT scans to measure macula thickness and vision tests to assess best-corrected visual acuity BCVA. Researchers also collect data on quality of life, safety, treatment use, and participant experiences. The primary outcome is vision measured at 104 weeks after randomisation. The study lasts about two years, with ongoing monitoring of treatment effects, side effects, and participant satisfaction to assess the potential for wider use of the combined treatment approach.
Actively Recruiting
Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.
Actively Recruiting
Researchers are evaluating depemokimab as a treatment for adults aged 40 to 80 years with moderate to severe chronic obstructive pulmonary disease COPD characterized by type 2 inflammation and frequent exacerbations. This Phase 3 trial aims to assess the efficacy and safety of depemokimab when added to standard care compared to a placebo with standard care. The study is sponsored by GlaxoSmithKline and focuses on reducing the rate of moderate to severe COPD exacerbations. Participants will receive either subcutaneous injections of depemokimab or placebo alongside their optimized inhaler therapies, which include inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta2-adrenergic agonists, all maintained for at least six months prior to the study. The study uses a randomized, double-blind, parallel-group design and lasts for up to 104 weeks, during which participants continue their standard care while receiving the study treatments. Throughout the study, participants will be regularly monitored for COPD exacerbations and changes in respiratory symptoms using validated tools like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms in COPD score. Researchers will also track emergency visits or hospitalizations related to exacerbations. Safety assessments and efficacy measurements will be collected throughout the two-year period to evaluate the impact of depemokimab as an add-on treatment.
Actively Recruiting
Researchers are evaluating the use of two types of MRI scans and two biopsy methods to improve prostate cancer diagnosis. The study focuses on whether biparametric MRI bpMRI, which is shorter and does not use contrast dye, can be an alternative to the longer multiparametric MRI mpMRI that uses gadolinium contrast. It also compares image-fusion targeted biopsy, which overlays MRI and ultrasound images during biopsy, with visual-registration targeted biopsy, where biopsy locations are chosen by looking at MRI images separately. Participants first receive either the mpMRI or bpMRI scan. If the MRI suggests cancer, the clinical team decides if a biopsy is needed. Those advised for biopsy undergo either a visual-registration targeted biopsy or an image-fusion targeted biopsy. Both biopsy methods include taking systematic tissue samples to check for cancer. The study does not blind participants or doctors to the MRI or biopsy type used. During the study, participants undergo MRI scans and possibly biopsies based on clinical advice. Researchers collect data on how many clinically significant prostate cancers are detected within 12 weeks of enrollment. They also assess any adverse events related to MRI and biopsy procedures, patient-reported outcomes, and accuracy of cancer detection using different scoring systems. The total duration for outcome assessment is up to 12 weeks after joining the study.
Actively Recruiting
Researchers are conducting a multi-centre observational study focused on children with rare inherited cardiac conditions, particularly those diagnosed with cardiomyopathy before age 16. The study aims to better understand the genetic and environmental factors influencing these heart muscle diseases, including disease progression and response to treatments. By collecting genetic information and clinical data, the study seeks to identify new personalized treatment options for affected children. Participants include children with diagnosed inherited cardiac conditions and their parents. The study collects baseline demographic, imaging, and genotyping data primarily from routine clinical care, including whole genome sequencing. Some participants may provide blood or saliva samples for genetic and biomarker analysis. Family members of deceased patients might also donate stored tissue or samples if available. The study plans to follow participants over a 5-year period. During the study, researchers will access clinical data including health information and results from routine tests like echocardiograms. Some procedures may involve minimal risk, such as blood or saliva collection. The study focuses on monitoring the participants health outcomes and genetic markers to understand disease progression. The total follow-up duration for each participant is up to five years, with data collected throughout this period.
1-10 of 16
1